DESCOVY Drug Patent Profile

When do Descovy patents expire, and what generic alternatives are available?

Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-eight patent family members in forty-two countries.

The generic ingredient in DESCOVY is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Descovy

A generic version of DESCOVY was approved as emtricitabine; tenofovir alafenamide fumarate by MACLEODS PHARMS LTD on April 7^th, 2026.

Summary for DESCOVY

International Patents:	58
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Patent Applications:	263
Drug Prices:	Drug price information for DESCOVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DESCOVY
What excipients (inactive ingredients) are in DESCOVY?	DESCOVY excipients list
DailyMed Link:	DESCOVY at DailyMed

See drug prices for DESCOVY

Recent Clinical Trials for DESCOVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE1
Johns Hopkins University	PHASE1
National University Hospital, Singapore	PHASE1

See all DESCOVY clinical trials

Pharmacology for DESCOVY

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for DESCOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	120 mg/15 mg	208215	1	2022-10-31
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	200 mg/25 mg	208215	6	2019-11-05

US Patents and Regulatory Information for DESCOVY

DESCOVY is protected by two US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No					Y
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016	AB	RX	Yes	Yes
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No

Expired US Patents for DESCOVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016

International Patents for DESCOVY

When does loss-of-exclusivity occur for DESCOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DESCOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	170750
Austria	219366
Austria	270291

Supplementary Protection Certificates for DESCOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	2016/014	Ireland		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061/001-EU/1/15/1061/002 20151119
0513200	91073	Luxembourg		91073, EXPIRES: 20160131
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130

DESCOVY: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market position of DESCOVY?

DESCOVY, a nucleotide analog reverse transcriptase inhibitor (NtRTI), is primarily indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and pediatric patients, as part of combination therapy. It is also approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents. DESCOVY is manufactured by Gilead Sciences.

The drug’s market presence is characterized by its dual utility in both treatment and prevention. In the treatment landscape, DESCOVY is a component of several highly effective antiretroviral therapy (ART) regimens. Its efficacy, safety profile, and tolerability have contributed to its established position within clinical guidelines. For PrEP, DESCOVY, in combination with emtricitabine (FTC), forms Truvada, and subsequently DESCOVY itself is used for PrEP in individuals for whom it is appropriate, based on certain risk factors and negative HIV status. The introduction of newer PrEP options, such as Apretude (cabotegravir extended-release injectable suspension), represents potential competition, although DESCOVY maintains a significant share due to its established use and oral administration.

Market penetration is influenced by factors including prescribing physician preference, patient adherence to oral medications, formulary access, and the evolving landscape of HIV prevention strategies. The global HIV market is substantial, with continued unmet needs in certain regions and populations, creating sustained demand for effective ART and PrEP agents.

What are the key patent protections and exclusivity periods for DESCOVY?

Gilead Sciences holds multiple patents covering DESCOVY (tenofovir alafenamide), its formulations, and methods of use. The primary compound patent for tenofovir alafenamide (TAF) is crucial. While the exact expiry dates of all patents are complex and can be subject to litigation and extensions, key patent families related to TAF generally extend into the late 2020s and early 2030s.

For example, U.S. Patent No. 8,759,317, which covers certain crystalline forms of tenofovir alafenamide, has been a subject of litigation. The listed expiry date for this patent is June 28, 2022, but exclusivities and potential patent term extensions (PTE) or adjustments can influence the actual market exclusivity. The U.S. Food and Drug Administration (FDA) Orange Book lists patents and exclusivities for approved drugs. For DESCOVY (tenofovir alafenamide), the listed patents and their expiry dates are critical for determining market exclusivity.

Key exclusivities include:

• New Chemical Entity (NCE) Exclusivity: Typically 5 years from approval, though this may be superseded by later-expiring compound patents.
• Orphan Drug Exclusivity (ODE): If applicable, it grants 7 years of exclusivity for a drug treating a rare disease. DESCOVY’s indications do not generally fall under ODE.
• Patent Term Extension (PTE): Granted to compensate for patent term lost due to regulatory review. PTE is often applied to the longest-running patent covering the drug.
• Hatch-Waxman Exclusivity: Other forms of market exclusivity can arise from specific regulatory pathways.

The expiration of primary patents is a significant event, paving the way for generic competition. Generic manufacturers typically await the expiration of all relevant patents and exclusivities before launching their versions. The timeline for generic entry for DESCOVY will be dictated by the expiry of the last of these protections.

What is the sales performance and financial trajectory of DESCOVY?

DESCOVY has demonstrated strong sales performance, contributing significantly to Gilead Sciences’ overall revenue. Sales figures are typically reported quarterly and annually.

Year	Global DESCOVY Net Product Sales (USD Billions)
2021	$6.48
2022	$7.01
2023	$7.08

Source: Gilead Sciences Investor Relations Reports and SEC Filings.

The financial trajectory has been one of consistent growth, driven by its dual role in HIV treatment and prevention. The PrEP market, in particular, has been a growth driver, though it faces increasing competition. The ART market is relatively stable, with DESCOVY being a foundational component of many regimens.

Factors influencing future trajectory include:

• Generic Entry: The onset of generic competition following patent expiries will directly impact DESCOVY’s sales volume and pricing power.
• New HIV Therapies: Development and approval of novel ART regimens, including long-acting injectables and potentially curative therapies, could shift market share.
• PrEP Market Evolution: The expansion of PrEP access and the introduction of alternative PrEP modalities (e.g., injectables) will influence DESCOVY's share in this segment.
• Geographic Expansion: Growth opportunities exist in emerging markets where HIV treatment and prevention access is expanding.
• COVID-19 Impact: While less direct now, past disruptions to healthcare access and clinical trials could have had residual effects on prescribing patterns.

Gilead Sciences’ strategy involves managing the lifecycle of its key products, including DESCOVY, by developing new formulations, combinations, and exploring new indications where applicable. However, the primary threat to revenue remains generic competition.

What is the competitive landscape for DESCOVY?

The competitive landscape for DESCOVY is segmented by its indications: HIV treatment and HIV prevention (PrEP).

In HIV Treatment: DESCOVY is rarely used as a monotherapy and is integrated into combination ART regimens. Competitors here are other antiretroviral drugs and complete regimens that may include different NRTIs, integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNIRIs), and protease inhibitors (PIs). Key competitors or components of competing regimens include:

• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide): Also from Gilead, Biktarvy is a complete single-tablet regimen (STR) that includes DESCOVY. Biktarvy has become a dominant force in treatment-naive and treatment-experienced patients, often considered a preferred regimen.
• Triumeq (dolutegravir/abacavir/lamivudine): A widely used INSTI-based STR from ViiV Healthcare.
• Dovato (dolutegravir/lamivudine): A two-drug STR from ViiV Healthcare, offering a simpler regimen for certain patients.
• Other STRs: Including Genentech/AbbVie’s Investigational drug Rilpivirine/Cabotegravir, and combinations from other manufacturers.

The trend in HIV treatment is towards STRs with high efficacy, good tolerability, and minimal drug-drug interactions. DESCOVY’s component in STRs like Biktarvy positions it favorably, but it also means that if a patient switches from a regimen containing DESCOVY to an entirely new STR, DESCOVY’s direct sales may be impacted.

In HIV Prevention (PrEP): DESCOVY, as part of FTC/TAF, was a key PrEP option. The competitive landscape here has evolved significantly:

• Truvada (emtricitabine/tenofovir disoproxil fumarate - TDF): The first FDA-approved PrEP medication. DESCOVY offers an alternative to Truvada with a potentially improved renal and bone safety profile due to TAF.
• Apretude (cabotegravir extended-release injectable suspension): Approved by the FDA in December 2021, Apretude is a long-acting injectable option for PrEP. It offers an alternative for individuals who prefer or struggle with daily oral pills. This represents a significant competitive shift, offering convenience and potentially improving adherence for some users.
• Generic Truvada: The availability of generic Truvada has made PrEP more accessible and affordable, increasing competition.
• Future Pipeline: Research continues into other novel PrEP modalities, including other long-acting injectables and potentially other drug classes.

The PrEP market is dynamic, with increasing public health initiatives to expand access. The choice between oral DESCOVY and injectable Apretude depends on individual patient preference, risk factors, and healthcare provider recommendations.

What is the regulatory status and potential for market expansion?

DESCOVY has received approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its approved indications. Regulatory filings and approvals are critical for market access and commercialization.

U.S. FDA Approvals:

• Treatment of HIV-1 infection: Approved in combination with other antiretroviral agents.
• Pre-Exposure Prophylaxis (PrEP): Approved for at-risk individuals to reduce sexual acquisition of HIV-1 infection.

European Medicines Agency (EMA) Approvals: Similar approvals have been granted in the European Union, facilitating market access across member states.

Market Expansion Potential:

• Geographic Expansion: While DESCOVY is available in developed markets, there is significant potential for expansion in low- and middle-income countries where the burden of HIV is high and access to effective ART and PrEP is expanding. Local regulatory approvals and pricing strategies are key to this expansion.
• New Indications: Research into new indications for TAF-based therapies is ongoing, though the primary focus remains on HIV. Investigating TAF in other viral infections or related conditions could offer future expansion opportunities, though these are speculative.
• Combination Therapies: The continued development of novel single-tablet regimens incorporating TAF, like Biktarvy, represents a form of market expansion and reinforcement of TAF’s utility.
• PrEP Uptake Growth: Continued efforts to increase PrEP uptake globally, coupled with patient education and access programs, can drive further market expansion for DESCOVY in its PrEP indication, despite the emergence of injectable options.

The primary regulatory hurdle for further market expansion in new territories is the process of securing local marketing authorizations, which involves submitting comprehensive dossiers of preclinical, clinical, and manufacturing data. Post-approval, pharmacovigilance and ongoing safety monitoring are also crucial.

Key Takeaways

• DESCOVY is a dual-indicated HIV drug for treatment and prevention (PrEP), holding a significant market position.
• Gilead Sciences holds extensive patent protection for DESCOVY, with key patents generally expiring in the late 2020s and early 2030s, signaling impending generic competition.
• DESCOVY has generated substantial revenue for Gilead Sciences, with sales exceeding $7 billion annually in recent years, though future growth will be impacted by patent expiries.
• The competitive landscape is robust, with Biktarvy (a STR containing DESCOVY) being a major internal competitor, and Apretude (an injectable PrEP) representing a new modality challenging DESCOVY’s PrEP market share.
• DESCOVY has broad regulatory approval in major markets, with continued potential for expansion in emerging economies and through its incorporation into next-generation combination therapies.

Frequently Asked Questions

1. When is the earliest DESCOVY is expected to face significant generic competition in the United States? The earliest significant generic competition is anticipated following the expiration of key patents and exclusivities, which generally extend into the late 2020s and early 2030s. Specific litigation outcomes and patent term extensions can influence this precise timeline.

2. What are the main advantages of DESCOVY over its predecessor, Truvada, for PrEP? DESCOVY, containing tenofovir alafenamide (TAF), is generally considered to have an improved renal and bone mineral density safety profile compared to Truvada, which contains tenofovir disoproxil fumarate (TDF). This is due to TAF’s more targeted delivery to lymphoid cells and lower plasma concentrations.

3. How does the emergence of long-acting injectable PrEP, such as Apretude, impact DESCOVY's market? Injectable PrEP options like Apretude offer an alternative administration route and may improve adherence for some individuals, posing a competitive challenge to oral DESCOVY. However, DESCOVY remains a primary option for those who prefer oral daily dosing or for whom injectables are not suitable.

4. What is the significance of DESCOVY being included in single-tablet regimens like Biktarvy? Its inclusion in STRs like Biktarvy solidifies DESCOVY’s position as a core component of modern HIV treatment. While this cannibalizes direct DESCOVY sales, it represents a successful lifecycle management strategy for Gilead and maintains the utility of the TAF moiety within their portfolio.

5. What are the primary hurdles for DESCOVY's market expansion into emerging economies? Key hurdles include obtaining local regulatory approvals, establishing appropriate pricing strategies that balance profitability with affordability, navigating complex distribution channels, and addressing potential barriers to healthcare access and patient education in these regions.

Citations

[1] Gilead Sciences, Inc. (n.d.). Investor Relations. Retrieved from [Gilead Sciences Investor Relations website] [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] [3] ViiV Healthcare. (n.d.). Product Information. (Various documents). [4] Genentech. (n.d.). Product Information. (Various documents).

DrugChatter Q&A for DESCOVY

Descovy generic availability 2026?
Descovy fda update 2025 2026?
Descovy fda approval date?
Descovy patent status price?
When does descovy patent expire?